Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

SafeLM Versus LMA Classic for Airway Management During Fibroadenoma Excision

2 octobre 2026 mis à jour par: Hanoi Medical University

Comparison of Airway Control Effectiveness of the SafeLM Video Laryngeal Mask and the LMA Classic in Patients Undergoing General Anesthesia for Fibroadenoma Excision

This randomized controlled trial compares the airway management performance of the SafeLM video laryngeal mask with the LMA Classic in adult patients undergoing elective fibroadenoma excision under general anesthesia. Participants will be randomly assigned to airway management with either the SafeLM or the LMA Classic. The primary outcome is oropharyngeal leak pressure. Secondary outcomes include insertion performance, ventilation parameters, hemodynamic responses, and airway-related adverse events.

Aperçu de l'étude

Statut

Pas encore de recrutement

Description détaillée

The SafeLM is a video-assisted laryngeal mask that allows visualization during placement, whereas the LMA Classic is a conventional supraglottic airway device. This study is designed to compare the clinical performance of these two devices under standardized conditions.

Adult patients scheduled for elective fibroadenoma excision under general anesthesia will be screened for eligibility. Only patients for whom both devices are considered clinically appropriate will be enrolled, thereby avoiding randomization when patient characteristics indicate a preference for a particular airway management technique. Eligible participants will be randomly assigned to airway management with either the SafeLM or the LMA Classic.

After standardized induction of general anesthesia, the assigned laryngeal mask will be inserted according to the study protocol. The primary outcome is oropharyngeal leak pressure after successful placement. Device insertion characteristics, ventilation parameters, hemodynamic responses, and airway-related adverse events will also be evaluated.

Type d'étude

Interventionnel

Inscription (Estimé)

132

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Female patients aged 18 years or older.
  • Scheduled for elective excision of benign breast fibroadenoma under general anesthesia.
  • Planned airway management with a laryngeal mask airway.
  • American Society of Anesthesiologists (ASA) physical status I-II.
  • Both the SafeLM and LMA Classic are considered clinically appropriate for airway management.
  • Provision of written informed consent.

Exclusion Criteria:

  • Increased risk of pulmonary aspiration, including inadequate preoperative fasting, full stomach, or gastrointestinal obstruction.
  • Known or suspected difficult airway or other airway characteristics for which random allocation between the two study devices is considered clinically inappropriate.
  • Upper airway pathology or anatomical abnormality that may interfere with laryngeal mask placement.
  • Clinical or surgical indication requiring tracheal intubation rather than a laryngeal mask airway.
  • Contraindication or known allergy to medications used in the standardized anesthesia protocol.
  • Inability to provide informed consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: SafeLM Video Laryngeal Mask

Participants randomized to this arm will receive airway management with the SafeLM video laryngeal mask during general anesthesia for elective fibroadenoma excision. The device will be inserted according to the standardized study protocol.

The SafeLM is a video-assisted supraglottic airway device that allows visualization of the laryngeal structures during insertion and positioning. It will be used for airway management during general anesthesia according to the standardized study protocol.

Comparateur actif: LMA Classic

Participants randomized to this arm will receive airway management with the LMA Classic during general anesthesia for elective fibroadenoma excision. The device will be inserted according to the standardized study protocol.

The LMA Classic is a conventional supraglottic airway device without video guidance. It will be used for airway management during general anesthesia according to the standardized study protocol.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Oropharyngeal Leak Pressure (OLP)
Délai: Immediately after successful laryngeal mask placement, before the start of surgery

Oropharyngeal leak pressure will be measured after successful placement of the assigned laryngeal mask and establishment of effective ventilation. OLP will be recorded in cmH2O as the airway pressure at which an audible oropharyngeal leak is detected during a standardized leak test.

Immediately after successful laryngeal mask placement, before the start of surgery

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
First-attempt insertion success
Délai: During initial laryngeal mask insertion

Proportion of participants in whom effective ventilation is achieved after the first insertion attempt of the assigned laryngeal mask.

During initial laryngeal mask insertion
Overall insertion success
Délai: During laryngeal mask insertion, up to 3 attempts

Proportion of participants in whom effective ventilation is achieved with the assigned laryngeal mask within the maximum number of insertion attempts permitted by the study protocol.

During laryngeal mask insertion, up to 3 attempts
Laryngeal mask insertion time
Délai: During laryngeal mask insertion

Time in seconds from introduction of the assigned laryngeal mask into the mouth until establishment of effective ventilation.

During laryngeal mask insertion
Number of insertion attempts
Délai: During laryngeal mask insertion

Number of attempts required to achieve successful placement and effective ventilation with the assigned laryngeal mask.

During laryngeal mask insertion
Need for additional airway maneuvers
Délai: During laryngeal mask insertion

Proportion of participants requiring additional maneuvers to achieve satisfactory placement and ventilation.

During laryngeal mask insertion
Peak inspiratory pressure
Délai: At 5 and 30 minutes after successful laryngeal mask placement

Peak inspiratory airway pressure measured in cmH2O during mechanical ventilation.

At 5 and 30 minutes after successful laryngeal mask placement
End-tidal carbon dioxide
Délai: At 5 and 30 minutes after successful laryngeal mask placement

End-tidal carbon dioxide (EtCO2) measured during mechanical ventilation.

At 5 and 30 minutes after successful laryngeal mask placement
Heart Rate
Délai: At baseline, immediately after successful laryngeal mask placement, and at 5 and 30 minutes after placement

Heart rate will be recorded in beats per minute (bpm).

At baseline, immediately after successful laryngeal mask placement, and at 5 and 30 minutes after placement
Blood staining on the laryngeal mask
Délai: Immediately after device removal

Presence of visible blood staining on the laryngeal mask after removal.

Immediately after device removal
Postoperative sore throat
Délai: At 1 and 24 hours after surgery

Presence of patient-reported sore throat following general anesthesia.

At 1 and 24 hours after surgery
Postoperative hoarseness
Délai: At 1 and 24 hours after surgery

Presence of patient-reported hoarseness following general anesthesia.

At 1 and 24 hours after surgery
Airway-related adverse events
Délai: From laryngeal mask insertion through postoperative observation, assessed up to 24 hours after surgery

Occurrence of airway-related adverse events, including laryngospasm and clinically evident regurgitation.

From laryngeal mask insertion through postoperative observation, assessed up to 24 hours after surgery
Arterial Pressure
Délai: At baseline, immediately after successful laryngeal mask placement, and at 5 and 30 minutes after placement

Arterial pressure will be recorded in mmHg.

At baseline, immediately after successful laryngeal mask placement, and at 5 and 30 minutes after placement

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 octobre 2026

Achèvement primaire (Estimé)

1 juin 2027

Achèvement de l'étude (Estimé)

1 juillet 2027

Dates d'inscription aux études

Première soumission

16 septembre 2026

Première soumission répondant aux critères de contrôle qualité

16 septembre 2026

Première publication (Réel)

23 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

7 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 octobre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner